SG11202109514VA - Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy - Google Patents

Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Info

Publication number
SG11202109514VA
SG11202109514VA SG11202109514VA SG11202109514VA SG11202109514VA SG 11202109514V A SG11202109514V A SG 11202109514VA SG 11202109514V A SG11202109514V A SG 11202109514VA SG 11202109514V A SG11202109514V A SG 11202109514VA SG 11202109514V A SG11202109514V A SG 11202109514VA
Authority
SG
Singapore
Prior art keywords
lnp
cancer immunotherapy
replicon rna
synthetic oncolytic
oncolytic
Prior art date
Application number
SG11202109514VA
Inventor
Darrell Irvine
Karl Wittrup
Ron Weiss
Yingzhong Li
Noor Momin
Yizhou Dong
Original Assignee
Massachusetts Inst Technology
Univ Ohio State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Univ Ohio State filed Critical Massachusetts Inst Technology
Publication of SG11202109514VA publication Critical patent/SG11202109514VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202109514VA 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy SG11202109514VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Publications (1)

Publication Number Publication Date
SG11202109514VA true SG11202109514VA (en) 2021-09-29

Family

ID=69526302

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109514VA SG11202109514VA (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Country Status (13)

Country Link
US (2) US11717548B2 (en)
EP (1) EP3934673A1 (en)
JP (1) JP7561134B2 (en)
KR (1) KR20220006041A (en)
CN (1) CN113966221A (en)
AU (1) AU2020233788A1 (en)
BR (1) BR112021017637A8 (en)
CA (1) CA3132714A1 (en)
CO (1) CO2021013417A2 (en)
IL (1) IL285963A (en)
MX (1) MX2021010808A (en)
SG (1) SG11202109514VA (en)
WO (1) WO2020185293A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113509542A (en) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 Medicine for expressing interleukin 12 and aiming at tumor based on mRNA and preparation method thereof
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN115227674B (en) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 Encapsulated oncolytic viral genetic material and uses thereof
WO2024149832A1 (en) * 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
CN118147171A (en) * 2024-03-08 2024-06-07 上海复诺健生物科技有限公司 Self-amplifying mRNA nucleic acid sequences with enhanced expression levels of exogenous genes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
BR112013000392B8 (en) * 2010-07-06 2022-10-04 Novartis Ag PHARMACEUTICAL COMPOSITION CONTAINING VIRION-LIKE DISTRIBUTION PARTICLE FOR SELF-REPLICATING RNA MOLECULES AND THEIR USE
EP2729168A2 (en) * 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
US9526772B2 (en) * 2012-12-03 2016-12-27 Ohio State Innovation Foundation Ehrlichial invasin for immunization, diagnosis, and cell delivery
WO2016037053A1 (en) * 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
KR20170074235A (en) * 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 Delivery of biomolecules to immune cells
US10369122B2 (en) 2015-05-21 2019-08-06 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
EP4185274A1 (en) * 2020-07-24 2023-05-31 Strand Therapeutics Inc. Lipidnanoparticle comprising modified nucleotides
US20240140960A1 (en) * 2021-02-12 2024-05-02 Ohio State Innovation Foundation Sugar derived lipid nanomaterials and uses thereof
JP2024527345A (en) * 2021-07-09 2024-07-24 リプリケイト バイオサイエンス，インコーポレイティド Modified Eastern Equine Encephalitis Viruses, Self-Replicating RNA Constructs, and Uses Thereof
CN117180454A (en) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 Compositions containing self-replicating RNA molecules and lipid nanoparticle delivery vehicles and methods of making the same

Also Published As

Publication number Publication date
CO2021013417A2 (en) 2022-01-17
KR20220006041A (en) 2022-01-14
WO2020185293A1 (en) 2020-09-17
US20200281994A1 (en) 2020-09-10
CA3132714A1 (en) 2020-09-17
US11717548B2 (en) 2023-08-08
BR112021017637A2 (en) 2021-11-09
US20240024394A1 (en) 2024-01-25
IL285963A (en) 2021-10-31
AU2020233788A1 (en) 2021-10-07
MX2021010808A (en) 2021-12-15
JP2022524391A (en) 2022-05-02
CN113966221A (en) 2022-01-21
BR112021017637A8 (en) 2022-08-16
JP7561134B2 (en) 2024-10-03
EP3934673A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
IL288754A (en) Compositions and methods for cancer immunotherapy
TWI799411B (en) Oncolytic virotherapy and immunotherapy
IL285963A (en) Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
EP3624810A4 (en) Nano-enabled immunotherapy in cancer
EP3866813A4 (en) Combinatorial cancer immunotherapy
EP3258967A4 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
EP3703711A4 (en) Compositions and methods for treating cancer with anti-ror1 immunotherapy
EP3247408A4 (en) Compositions and methods for cancer immunotherapy
IL289585A (en) Dll3-targeting antibodies and uses thereof
EP3500262A4 (en) Compositions and methods for cancer immunotherapy
EP3752194A4 (en) Compositions and methods for tumor immunotherapy
EP3892333A4 (en) Tumor combined immunotherapy
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
EP3681903A4 (en) Compositions and methods for treating cancer with anti-cd19 immunotherapy
EP4045054A4 (en) Nano-enabled immunotherapy in cancer
EP3310915A4 (en) Tumor immunotherapy
IL291027A (en) Anti-steap1 antibodies and uses thereof
EP4076526A4 (en) Novel ddr1 antibodies and uses thereof
IL283076A (en) Methods and compositions for cancer immunotherapy
EP4025204A4 (en) Cancer immunotherapy
IL289335A (en) Novel cancer antigens and methods
IL289334A (en) Novel cancer antigens and methods
IL289205A (en) Novel cancer antigens and methods
IL289200A (en) Novel cancer antigens and methods
IL291550A (en) Anti-il-27 antibodies and uses thereof